Context Therapeutics Q2 net loss widens on higher R&D costs

Context Therapeutics

05/08/2026 21:58

Overview
US biopharma reported Q2 net loss widened yr/yr on higher R&D expenses
Company discontinued CT-95 to focus on CTIM-76 and CT-202 clinical programs
Cash and equivalents of $43 mln expected to fund operations into Q4 2027

Outlook
Company expects initial clinical readouts from CTIM-76 and CT-202 programs beginning in Q2 2027
Context expects cash and cash equivalents to fund operations into Q4 2027
Company plans to initiate CTIM-76 Phase 1b dose expansion trial in Q1 2027

Result Drivers
HIGHER R&D EXPENSES - Co said increased Q2 R&D expenses were mainly due to a $6.5 mln charge for amending the BioAtla license agreement for CT-202 and higher CTIM-76 costs
PORTFOLIO PRIORITIZATION - Co discontinued CT-95 and focused resources on CTIM-76 and CT-202 clinical programs
HIGHER ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher professional fees and personnel-related costs

Company press release: ID:nGNX9L1bCz

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$14.6 mln
 
Q2 Loss Per Basic Share
 
$0.15
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Context Therapeutics Inc is $5.00, about 704.1% above its August 4 closing price of $0.62

Reuters Recommended Reads
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise
Aug 5 - Immuneering expects cash runway to fund operations into 2029
Aug 5 - Compass Pathways' Q2 loss widens on commercial readiness activity costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)